TSX:BLU (Bellus Health)
About BLU
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Bellus Health (TSX: BLU) Latest News

Investing
2022’s Top Small Caps on the TSX: Are They Buys Today?

Dividend Stocks
3 Biotech Stocks to Buy Before the Down Market Is Over

Investing
2 Biotech Stocks to Buy Before the Down Market Recovers

Dividend Stocks
3 Growth Stocks You Can Buy Right Now with Less Than $100

Investing
2 Best Healthcare Stocks to Buy Right Now

Investing
2 Top Healthcare Stocks Defying the Bear Market

Investing
3 Growth Stocks up Over 50% in 2022

Dividend Stocks
3 Stocks To Keep Your Retirement Savings Growing Faster Than Inflation

Page
Top Biotech Stocks in Canada of 2023

Investing
3 Simple TSX Stocks to Buy With $25 Right Now

Investing
TFSA Investors: 3 Stocks That Haven’t Lost Money in 2022
